NGM Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NGM Biopharmaceuticals (NGM) announced that CEO David J. Woodhouse, Ph.D., will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 AM PST/10:30 AM EST. The presentation will be available via a live audio webcast on NGM’s website, with an archived version accessible for 30 days post-event. NGM focuses on developing innovative therapeutics for retinal diseases, cancer, and metabolic conditions, currently advancing seven programs including four in Phase 2/2b studies.
Details
News Market Reaction – NGM
The recorded move for NGM in the trading session of this news was -0.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13th at 7:30 AM PST/10:30 AM EST.
A live audio webcast of the presentation will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. An archived replay of the webcast will be available on the Company’s website for 30 days following the presentation.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying retinal diseases, cancer and liver and metabolic diseases. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. All of our therapeutics have been generated by our in-house discovery engine; today, we have seven disclosed programs, including four in Phase 2 or 2b studies, across three therapeutics areas. Visit us at www.ngmbio.com for more information.
| Investor Contact: Brian Schoelkopf ir@ngmbio.com | Media Contact: media@ngmbio.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.